Company

Recce Pharmaceuticals Ltd

Headquarters: Sydney, NSW, Australia

CEO: Mr. James Hamilton-Bray Graham GAICD

ASX: RCE +4.17%

Market Cap

A$97.9 Million

AUD as of July 1, 2024

US$65.2 Million

Market Cap History

Recce Pharmaceuticals Ltd market capitalization over time

Evolution of Recce Pharmaceuticals Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Recce Pharmaceuticals Ltd

Detailed Description

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Recce Pharmaceuticals Ltd has the following listings and related stock indices.


Stock: ASX: RCE wb_incandescent

Stock: FSX: R9Q wb_incandescent

Details

Headquarters:

Gateway Tower

Level 36 1 Macquarie Place

Sydney, NSW 2000

Australia

Phone: 61 2 8075 4585

Fax: 61 2 8075 4584